Key result
ARB treatment with olmesartan increased daytime natriuresis from 4.5 to 5.5 mmol/h (P=0.002) and significantly reduced tubular sodium reabsorption (P=0.0005).
Why the study?
Does olmesartan shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption in patients with chronic kidney disease?
Observational (n=41)
Does olmesartan shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption in patients with chronic kidney disease?
Olmesartan shifts the circadian blood pressure rhythm to a dipper pattern in patients with chronic kidney disease by suppressing tubular sodium reabsorption and enhancing daytime natriuresis.
Supports natriuresis mechanism for olmesartan in CKD; leaves open effects on circadian BP dipping pending randomized trials.
Recently, we found that an angiotensin II receptor blocker (ARB) restored the circadian rhythm of the blood pressure (BP) from a nondipper to a dipper pattern, similar to that achieved with sodium intake restriction and diuretics (Fukuda M, Yamanaka T, Mizuno M, Motokawa M, Shirasawa Y, Miyagi S, Nishio T, Yoshida A, Kimura G. J Hypertens 26: 583-588, 2008). ARB enhanced natriuresis during the day, while BP was markedly lower during the night, resulting in the dipper pattern. In the present study, we examined whether the suppression of tubular sodium reabsorption, similar to the action of diuretics, was the mechanism by which ARB normalized the circadian BP rhythm. BP and glomerulotubular balance were compared in 41 patients with chronic kidney disease before and during ARB treatment with olmesartan once a day in the morning for 8 wk. ARB increased natriuresis (sodium excretion rate; U(Na)V) during the day (4.5 ± 2.2 to 5.5 ± 2.1 mmol/h, P = 0.002), while it had no effect during the night (4.3 ± 2.0 to 3.8 ± 1.6 mmol/h, P = 0.1). The night/day ratios of both BP and U(Na)V were decreased. The decrease in the night/day ratio of BP correlated with the increase in the daytime U(Na)V (r = 0.42, P = 0.006). Throughout the whole day, the glomerular filtration rate (P = 0.0006) and tubular sodium reabsorption (P = 0.0005) were both reduced significantly by ARB, although U(Na)V remained constant (107 ± 45 vs. 118 ± 36 mmol/day, P = 0.07). These findings indicate that the suppression of tubular sodium reabsorption, showing a resemblance to the action of diuretics, is the primary mechanism by which ARB can shift the circadian BP rhythm into a dipper pattern.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (2011) conducted an observational in chronic kidney disease (n=41). Olmesartan (ARB) vs. Baseline (before ARB treatment) was evaluated on Daytime natriuresis (sodium excretion rate; U(Na)V) (p=0.002). ARB treatment with olmesartan increased daytime natriuresis from 4.5 to 5.5 mmol/h (P=0.002) and significantly reduced tubular sodium reabsorption (P=0.0005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: